What question did this study set out to answer?

Summarize emerging therapeutic drug targets, preclinical cellular and animal models, and early clinical trials for axial spondyloarthritis.

August 3, 2021Expert Opinion on Therapeutic Targets

Axial spondyloarthritis: emerging drug targets

View Full Paper

Ask AI

Bookmark

Authors

BCBilade Cherqaoui LALuiza M. Araujo SGSimon Glatigny

Discussion

Member takes

Overview

Expert review reveals emerging cytokine pathways and targets in axial spondyloarthritis, indicating novel approaches to control bone formation and achieve remission.

Key Points

Summarize emerging therapeutic drug targets, preclinical cellular and animal models, and early clinical trials for axial spondyloarthritis.
Evaluated molecular mechanisms from preclinical animal models, cellular systems, and phase-II clinical trials in axial spondyloarthritis.
Assessed target pathways including type 3 immune cascades, growth factor signaling, and artificial intelligence-assisted patient stratification.
Targeting the transforming growth factor-β family represents a leading strategy to directly modulate pathological new bone formation.
Blockade of granulocyte-macrophage colony-stimulating factor suppresses hyperactive type 3 immune responses driving systemic inflammation.
Cytokine modulation using interleukin-2 or interleukin-27 promotes regulatory anti-inflammatory responses capable of supporting sustained drug-free remission.

Cite This Study

Cherqaoui et al. (2021) studied this question.

synapsesocial.com/papers/6a9cd6dc60ceabfff382cf0e https://doi.org/10.1080/14728222.2021.1973429

View Full Paper

Ask AI

Bookmark

August 3, 2021Expert Opinion on Therapeutic Targets

Axial spondyloarthritis: emerging drug targets

View Full Paper

Ask AI

Bookmark

Authors

BCBilade Cherqaoui LALuiza M. Araujo SGSimon Glatigny

Discussion

Member takes

Overview

Expert review reveals emerging cytokine pathways and targets in axial spondyloarthritis, indicating novel approaches to control bone formation and achieve remission.

Key Points

Summarize emerging therapeutic drug targets, preclinical cellular and animal models, and early clinical trials for axial spondyloarthritis.
Evaluated molecular mechanisms from preclinical animal models, cellular systems, and phase-II clinical trials in axial spondyloarthritis.
Assessed target pathways including type 3 immune cascades, growth factor signaling, and artificial intelligence-assisted patient stratification.
Targeting the transforming growth factor-β family represents a leading strategy to directly modulate pathological new bone formation.
Blockade of granulocyte-macrophage colony-stimulating factor suppresses hyperactive type 3 immune responses driving systemic inflammation.
Cytokine modulation using interleukin-2 or interleukin-27 promotes regulatory anti-inflammatory responses capable of supporting sustained drug-free remission.

Cite This Study

Cherqaoui et al. (2021) studied this question.

synapsesocial.com/papers/6a9cd6dc60ceabfff382cf0e https://doi.org/10.1080/14728222.2021.1973429

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark